Journal Website: https://www.icjn.net/cl ISSN: 3106-5058 | EISSN: 3106-5066

ICJN Press

Cytotherapy and Longevity (CL)

Volume. 01 | Issue. 01 | Aug. 2026 DOI: 10.66729/cl202603001

EDITORIAL

Inaugural Editorial

Ping Zhang[1,2,3*]

1 Center for Health Science and Engineering, Hebei Key Laboratory of Biomaterials and Smart Theranostics, School of Health Sciences and Biomedical Engineering, Hebei University of Technology, Tianjin 300131, China.
2 Department of Human Anatomy, School of Basic Medical Sciences, Tianjin Medical University, Tianjin 300070, China.
3 Key Laboratory of Hormones and Development (Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, Tianjin Medical University, Tianjin 300134, China.

*Corresponding Author: Ping Zhang, E-mail: pizhang2008@163.com

Population aging has become a major social and medical challenge worldwide. Age-related degenerative changes in the musculoskeletal system not only substantially impair physical function and quality of life, but also impose profound burdens on public health systems and broader social development. Accordingly, delaying aging, maintaining bodily function, and promoting healthy longevity have become increasingly important goals in the life sciences and medical research.

In recent years, advances in cell biology, immunotherapy, genetic engineering, and regenerative medicine have reshaped our understanding of aging, frailty, tissue repair, and the fundamental limits of human health. With the deepening integration of tissue engineering and regenerative medicine across multiple fields, the underlying mechanisms of aging and disease development are gradually being elucidated. Cell therapy, as an important pillar of regenerative medicine, offers new therapeutic opportunities for various degenerative diseases, frailty syndromes, chronic diseases, and age-related functional decline. At the same time, the biological mechanisms of aging are intrinsically linked to the therapeutic potential of cells.

Against the backdrop of growing societal need and advances in the field, and with the joint support of the China Laboratory Industry-University-Research Collaborative Innovation Platform and ICJN Press, I am honored, on behalf of the Editorial Board, to announce the launch of *Cytotherapy and Longevity (CL)*. Guided by the core mission of promoting human health and functional longevity through cell therapy. *CL* is committed to advancing collaborative innovation in cell therapy, mechanobiology, and the prevention and treatment of degenerative diseases.

CL focuses on the multidisciplinary field at the intersection of cell therapy and human aging, encompassing the full continuum from fundamental research to clinical translation. Its scope includes various cell types from diverse sources and their mechanobiological regulatory mechanisms; the development and clinical translation of cell therapies targeting multiple frailty-related diseases; cell culture and process optimization using physical regulation techniques in mechanobiological microenvironments; cell function testing and the use of clinical efficacy data; the development of intelligent mechanobiological intervention technologies and equipment; and validation of cell therapy efficacy in degenerative diseases. The journal also promotes the translational application of innovative technologies from mechanomedicine, mechanotherapy, biomechanics, and mechanobiology in integrated mechano-immuno-regenerative therapies.

To comprehensively present the latest achievements and emerging trends in this field, *CL* will feature dedicated sections for Reviews and Perspectives, Technical Communications, and Case Studies. These sections will bring together cutting-edge perspectives and practical experience from scholars in China and abroad. They will also systematically present recent advances in cell therapy for delaying physical decline, enhancing motor function, and improving quality of life, while providing technical support for related clinical practice and industrial development.

As a newly launched open-access academic journal, *CL* is committed to maintaining a rigorous double-blind peer-review process and the highest standards of academic excellence. To encourage the publication of innovative, scientifically rigorous, and clinically translatable research, the journal will waive article processing charges (APCs) during its launch period. *CL*'s development relies on the support and participation of colleagues across the global academic and industrial communities. We sincerely invite researchers, clinical experts, and engineering and technical professionals to submit their work, share findings, exchange ideas, and jointly explore emerging trends and practical innovations in cell therapy and longevity research. Going forward, the journal will continue to appoint leading international experts to strengthen its Editorial Board.

We look forward to working with the global academic community and all those involved in the journal — the editorial office, Editorial Board members, authors, reviewers, readers, and publishers — to advance cell therapy and longevity research and contribute new scientific insights to human health and well-being.

May *CL* serve as an important academic platform for

Copyright:© 2026 The Author(s). Published by ICJN Press.
This is an open access article under the https://creativecommons.org/licenses/by/4.0/
Received 28 March 2026; Revised 22 June 2026; Accepted 28 June 2026; Available online 20 August 2026.

connecting ideas, fostering innovation, and shaping the future.

Conflict of Interest

The author declares that there is no conflict of interest.

About the Journal

Cytotherapy and Longevity (CL), adhering to its core mission of "promoting human health and functional longevity through cell therapy," is committed to advancing collaborative innovation in cell therapy, mechanobiology, and the prevention and treatment of degenerative diseases. The journal focuses on the multidisciplinary field of cell therapy related to human aging, covering the entire industry chain of research, including various cell types from different sources and their mechanobiological regulatory mechanisms, the development and clinical translation of cell therapies targeting multiple frailty-related diseases, cell culture and process optimization using physical regulation techniques in a mechanobiological microenvironment, cell function testing and the application of clinical efficacy data, the development of intelligent mechanobiological intervention technologies and equipment, and the validation of the efficacy of cell therapy in degenerative diseases. It also promotes the translational application of innovative technologies from mechanomedicine, mechanotherapy, biomechanics, and mechanobiology in combined mechano-immuno-regenerative therapies. To comprehensively present the latest achievements and development trends in this field, *CL* will feature special columns such as reviews and outlooks, technical exchanges, and case studies to gather cutting-edge perspectives and practical experiences from scholars both domestically and internationally; systematically introduce the latest advances in cell therapy in delaying physical decline, enhancing motor function, and improving quality of life; and provide technical support for related clinical practices and industrial development. https://www.icjn.net/cl

Editors-in-Chief

Prof. Ping Zhang is a Chair of the Department of Anatomy, Histology, and Embryology at Tianjin Medical University. After graduating from Peking University Health Science Center, he held faculty positions at the Chinese Academy of Medical Sciences and Peking Union Medical College, followed by appointments as a postdoctoral fellow and research professor at Indiana University. His research focuses on bone metabolism and remodeling, stem cell differentiation, and the treatment of orthopedic diseases. Since becoming Chair of the Department in 2013, he has led the development of several municipal-level key courses, including Human Anatomy and Histology & Embryology, and has overseen national-level courses such as Systemic Anatomy and Human Anatomy for international students. He has also served as an editor, co-editor, or editorial board member for 14 national textbooks. His work in stem cells and regenerative medicine explores the mobilization of endogenous stem cells for disease treatment and has been supported by the NIH, the U.S. Department of Defense, NASA, the National Natural Science Foundation of China, and Tianjin's Applied Basic and Frontier Technology Research Program. He has published over 160 papers, participated in more than 90 international conferences, and delivered more than 30 invited keynote lectures.